LPTX Cypherpunk Technologies Inc.


$ 2.38 $ -0.52 (-17.82 %)    

Friday, 21-Nov-2025 12:37:08 EST
QQQ $ 592.45 $ 5.12 (0.87 %)
DIA $ 464.78 $ 5.35 (1.16 %)
SPY $ 661.37 $ 6.42 (0.98 %)
TLT $ 89.23 $ -0.43 (-0.48 %)
GLD $ 375.49 $ 1.50 (0.4 %)
$ 2.94
$ 2.89
$ 2.38 x 1
$ 2.40 x 1,400
$ 2.17 - $ 2.89
$ 0.22 - $ 3.70
36,900,888
na
na
$ 1.46
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-leap-therapeutics-stock-on-thursday

Leap Therapeutics shares are plunging after rebranding as Cypherpunk, pivoting to a Zcash treasury and announcing a $200M stock...

 leap-therapeutics-q3-eps-008-beats-024-estimate

Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0...

 leap-therapeutics-reports-final-results-from-part-b-of-defiance-study-phase-2-study-of-sirexatamab-in-mss-crc-patients-who-have-received-one-prior-systemic-therapy-for-advanced-disease

Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high populationIncreasing DKK1 levels furt...

 why-is-leap-therapeutics-down-9-in-pre-market-trading

Leap Therapeutics is trading lower in pre-market following a $58.9 million private placement led by Winklevoss Capital.

 leap-therapeutics-secures-589m-pipe-led-by-winklevoss-capital-for-9585m-shares-and-warrants-to-buy-719m-shares

Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION